|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 November 2000, Vol. 96, No. 9, pp. 3181-3187
NEOPLASIA
In vitro and in vivo production of vascular endothelial growth
factor by chronic lymphocytic leukemia cells
Haijuan Chen,
Andy T. Treweeke,
Dave C. West,
Kathleen J. Till,
John C. Cawley,
Mirko Zuzel, and
Cheng H. Toh
From the Departments of Haematology and Immunology,
University of Liverpool, Liverpool, United Kingdom.
Expansion of primary solid tumors and their malignant
dissemination are angiogenesis-dependent. Vascular endothelial growth factor (VEGF) is the key factor playing a pivotal role in solid tumor-induced angiogenesis. Recent studies indicate that angiogenesis may also be involved in the pathogenesis of certain hemic malignancies, including B-cell chronic lymphocytic leukemia (B-CLL). Mechanisms underlying angiogenesis in B-CLL and the role of VEGF in this process
are incompletely understood. In this study, it was examined whether
angiogenically functional VEGF is produced by B-CLL cells. Immunohistochemical staining with antibodies against VEGF and CD34, an
endothelial cell marker, demonstrated the presence of VEGF protein and
abundant blood vessels in infiltrated lymphoreticular tissues. Low
levels of VEGF were detected by ELISA in the culture media of
unstimulated cells; this was enhanced up to 7-fold by hypoxic
stimulation. SDS-PAGE and Western blot analysis of the concentrated
culture media showed 2 isoforms of VEGF protein with molecular weights
of 28 and 42 kd, respectively. RNA hybridization showed that these
cells expressed VEGF mRNA. Reverse transcription-polymerase chain reaction, combined with nucleotide sequence analysis, revealed that the predominantly expressed isoforms were VEGF121 and VEGF165. Moreover, 3H-thymidine incorporation and an in vivo
angiogenic assay demonstrated that the VEGF produced by CLL cells can
induce angiogenesis by stimulating endothelial cell proliferation. In
conclusion, this study shows that B-CLL cells produce VEGF and
demonstrates the angiogenic effects of this growth factor, which may be
relevant for the tissue phase of the disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. E. M. Patten, A. G. S. Buggins, J. Richards, A. Wotherspoon, J. Salisbury, G. J. Mufti, T. J. Hamblin, and S. Devereux
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
Blood,
May 15, 2008;
111(10):
5173 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Molica, M. Montillo, D. Ribatti, R. Mirabelli, A. Tedeschi, F. Ricci, S. Veronese, A. Vacca, and E. Morra
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia
Haematologica,
October 1, 2007;
92(10):
1367 - 1374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Szodoray, P. Alex, M. B. Frank, M. Turner, S. Turner, N. Knowlton, C. Cadwell, I. Dozmorov, Y. Tang, P. C. Wilson, et al.
A genome-scale assessment of peripheral blood B-cell molecular homeostasis in patients with rheumatoid arthritis
Rheumatology,
December 1, 2006;
45(12):
1466 - 1476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Redondo-Munoz, E. Escobar-Diaz, R. Samaniego, M. J. Terol, J. A. Garcia-Marco, and A. Garcia-Pardo
MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by {alpha}4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration
Blood,
November 1, 2006;
108(9):
3143 - 3151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Buckstein, R. S. Kerbel, Y. Shaked, R. Nayar, C. Foden, R. Turner, C. R. Lee, D. Taylor, L. Zhang, S. Man, et al.
High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
September 1, 2006;
12(17):
5190 - 5198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Carew, S. T. Nawrocki, Y. V. Krupnik, K. Dunner Jr, D. J. McConkey, M. J. Keating, and P. Huang
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL
Blood,
January 1, 2006;
107(1):
222 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Till, D. G. Spiller, R. J. Harris, H. Chen, M. Zuzel, and J. C. Cawley
CLL, but not normal, B cells are dependent on autocrine VEGF and {alpha}4{beta}1 integrin for chemokine-induced motility on and through endothelium
Blood,
June 15, 2005;
105(12):
4813 - 4819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Chiorazzi, K. R. Rai, and M. Ferrarini
Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
February 24, 2005;
352(8):
804 - 815.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood,
February 15, 2005;
105(4):
1383 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
Blood,
August 1, 2004;
104(3):
788 - 794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. K. Stevenson and F. Caligaris-Cappio
Chronic lymphocytic leukemia: revelations from the B-cell receptor
Blood,
June 15, 2004;
103(12):
4389 - 4395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mor, F. J. Quintana, and I. R. Cohen
Angiogenesis-Inflammation Cross-Talk: Vascular Endothelial Growth Factor Is Secreted by Activated T Cells and Induces Th1 Polarization
J. Immunol.,
April 1, 2004;
172(7):
4618 - 4623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Orsini, A. Guarini, S. Chiaretti, F. R. Mauro, and R. Foa
The Circulating Dendritic Cell Compartment in Patients with Chronic Lymphocytic Leukemia Is Severely Defective and Unable to Stimulate an Effective T-Cell Response
Cancer Res.,
August 1, 2003;
63(15):
4497 - 4506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Decker, S. Hipp, I. Ringshausen, C. Bogner, M. Oelsner, F. Schneller, and C. Peschel
Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
Blood,
January 1, 2003;
101(1):
278 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Schuch, M. Machluf, G. Bartsch Jr, M. Nomi, H. Richard, A. Atala, and S. Soker
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo
Blood,
December 15, 2002;
100(13):
4622 - 4628.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol.,
November 1, 2002;
20(21):
4368 - 4380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Molica, A. Vacca, D. Ribatti, A. Cuneo, F. Cavazzini, D. Levato, G. Vitelli, L. Tucci, A. M. Roccaro, and F. Dammacco
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia
Blood,
October 16, 2002;
100(9):
3344 - 3351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Franz Alber, J. Dulak, M. Frick, W. Dichtl, S. Paul Schwarzacher, O. Pachinger, and F. Weidinger
Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease
J. Am. Coll. Cardiol.,
June 19, 2002;
39(12):
1951 - 1955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood,
May 1, 2002;
99(9):
3383 - 3389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verstovsek, H. Kantarjian, T. Manshouri, J. Cortes, F. J. Giles, A. Rogers, and M. Albitar
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia
Blood,
March 15, 2002;
99(6):
2265 - 2267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2002;
2002(1):
193 - 213.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
24 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Jing, C. Beesley, C. S. Foster, H. Chen, P. S. Rudland, D. C. West, H. Fujii, P. H. Smith, and Y. Ke
Human Cutaneous Fatty Acid-binding Protein Induces Metastasis by Up-Regulating the Expression of Vascular Endothelial Growth Factor Gene in Rat Rama 37 Model Cells
Cancer Res.,
June 1, 2001;
61(11):
4357 - 4364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Peterson, A. R. Kini, and N. Kay
Angiogenesis is increased in B-cell chronic lymphocytic leukemia
Blood,
April 15, 2001;
97(8):
2529 - 2530.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
